重组人血管内皮抑制素联合TP方案治疗卵巢癌的近期疗效.docVIP

重组人血管内皮抑制素联合TP方案治疗卵巢癌的近期疗效 　　【摘要】 目的：研究重组人血管内皮抑制素（恩度）联合多西他赛和顺铂（TP方案）治疗卵巢癌的近期疗效。方法：选取2010年4月-2011年1月于笔者所在医院就诊并治疗的卵巢癌病患38例，按数字表法随机分为观察组（n=19）和对照组（n=19）。观察组病患采用重组人血管内皮抑制素联合TP方案进行治疗，对照组病患则单独使用TP方案进行治疗，对比两组疗效及对血液指标水平的影响。结果：观察组中CR占比及有效率分别为52.6%（10/19）和89.5%（17/19），均显著高于对照组的21.1%（4/19）与57.9%（11/19），差异均有统计学意义（均P0.05）。观察组血红蛋白、白细胞及血小板含量分别为（9.86±3.48）g/100 ml，（3.62±1.19）×103/m3 ，（8.83±2.58）×104/m3，均显著高于对照组的（7.13±2.14）g/100 ml，（2.54±0.76）×103/m3及（6.56±1.87）×104/m3，差异均有统计学意义（均P0.05）。结论：重组人血管内皮抑制素联合TP方案治疗卵巢癌疗效显著，能缓解病患临床症状，患者耐受性良好，且毒性较低，安全性较好，值得临床推荐。 　　【关键词】 重组人血管内皮抑制素； TP方案； 毒副反应； 卵巢癌 　　中图分类号 R737.31 文献标识码 A 文章编号 1674-6805（2014）13-0003-02 　　Efficacy of Recombinant Human Endostatin Combined with TP Regimen in the Treatment of Ovarian Cancer/LIU Guo-hua.//Chinese and Foreign Medical Research，2014，12（13）：3-4 　　【Abstract】 Objective：To study the curative effect of Recombinant Human Endostatin combined with Docetaxel and Cisplatin（TP regimen） in the treatment of ovarian cancer.Method：From April 2010 to January 2011 in our hospital，38 cases with ovarian cancer，according to random number table they were randomly divided into observation group（n=19） and control group（n=19）.Patients in observation group were treated by Recombinant Human Endostatin combined with TP scheme，patients in control group were alone given TP regimen，compared curative effect of two treatment methods and hematological indexes.Result：The observation group’s CR accounting and the effective rate were 52.6%（10/19） and 89.5%（17/19），were significantly higher than those in control group of 21.1%（4/19） and 57.9% （11/19），the differences were statistically significant（P0.05）.The hemoglobin， white cells and platelets of observation group were （9.86±3.48）g/100 ml， 　　（3.62±1.19）×103/m3，（8.83±2.58）×104/m3，were significantly higher than those in control group （7.13±2.14）g/100 ml，（2.54±0.76）×103/m3 and （6.56±1.87）×104/m3，the differences were statistically significant（P0.05）.Conclusion：The efficacy Recombinant Human Endosta